Explore /
Poster
/ Clinical benefit of luspatercept treatment (tx) in transfusion-dependent (TD), erythropoiesis-stimulating agent (ESA)–naive patients (pts) with very low-, low- or intermediate-risk myelodysplastic syndromes (MDS) in the COMMANDS trial.

Clinical benefit of luspatercept treatment (tx) in transfusion-dependent (TD), erythropoiesis-stimulating agent (ESA)–naive patients (pts) with very low-, low- or intermediate-risk myelodysplastic syndromes (MDS) in the COMMANDS trial.

Authors

Amer Methqal Zeidan

Department of Internal Medicine, Yale School of Medicine and Yale Cancer Center, Yale University, New Haven, CT

Amer Methqal Zeidan , Uwe Platzbecker , Matteo Giovanni Della Porta , Valeria Santini , Guillermo Garcia-Manero , Jiahui Li , Sandra Kreitz , Veronika Pozharskaya , Shelonitda Rose , Yinzhi Lai , David Valcárcel , Pierre Fenaux , Jake Shortt , Rami S. Komrokji

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Track

Hematologic Malignancies

Sub Track

Myelodysplastic Syndromes (MDS)

Clinical Trial Registration Number

NCT03682536

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr 6565)

DOI

10.1200/JCO.2024.42.16_suppl.6565

Abstract #

6565

Poster Bd #

124

Abstract Disclosures

Similar Posters

Poster

2020 ASCO Virtual Scientific Program

Clinical benefit of luspatercept in patients (pts) with lower-risk MDS (LR-MDS) and high transfusion burden in the phase III MEDALIST study.

First Author: Amer Methqal Zeidan

Poster

2012 ASCO Annual Meeting

Results of a phase II trial of azacitidine (AZA) with or without epoetin beta (EPO) in lower-risk MDS.

First Author: Claude Gardin

Poster

2024 ASCO Annual Meeting

Impact of pacritinib on symptoms in with thrombocytopenia and myelofibrosis who require red blood cell transfusion.

First Author: Stephen Oh

Poster

2023 ASCO Quality Care Symposium

Clinical and economic effects of technology updates to the electronic health record for the management of erythopoetic stimulating agents and MDS-associated anemia.

First Author: Steven Gilmore

FEATURED

Clinical benefit of luspatercept treatment (tx) in transfusion-dependent (TD), erythropoiesis-stimulating agent (ESA)–naive patients (pts) with very low-, low- or intermediate-risk myelodysplastic syndromes (MDS) in the COMMANDS trial.

Authors

Amer Methqal Zeidan

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Poster Details

Meeting

Session Type

Session Title

Track

Sub Track

Clinical Trial Registration Number

Citation

DOI

Abstract #

Poster Bd #

Similar Posters

Poster

Clinical benefit of luspatercept in patients (pts) with lower-risk MDS (LR-MDS) and high transfusion burden in the phase III MEDALIST study.

Poster

Results of a phase II trial of azacitidine (AZA) with or without epoetin beta (EPO) in lower-risk MDS.

Poster

Impact of pacritinib on symptoms in with thrombocytopenia and myelofibrosis who require red blood cell transfusion.

Poster

Clinical and economic effects of technology updates to the electronic health record for the management of erythopoetic stimulating agents and MDS-associated anemia.